A drug to treat a rare muscle disease which affects some 20 children in the Netherlands a year should not be included in the basic insurance package unless the price is halved, government advisory group Zorginstituut Nederland has said in new recommendations.
In addition, pharmaceutical company Novartis should also agree to payment on the basis of the actual results, the institute said. Zolgensma, known as the most expensive drug in the world, is used to treat spinal muscular dystrophy (SMA) and costs €1.9m per treatment. The institute estimates that if the cost were halved, the drug would add some €11m to the Dutch healthcare budget a year.
Read more at:
World's most expensive drug may not be covered by Dutch insurance - DutchNews.nl
The Future Is Here Today
Where Business, Nature and Leisure Provide An Ideal Setting For Living
